Drug-Eluting Balloon Catheters Market Size By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use (Hospitals and Clinics,

Drug-Eluting Balloon Catheters Market Size By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories) Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2030

The global drug-eluting balloon catheters market is anticipated to register considerable gains through 2030, driven by rising geriatric population. Meanwhile, increasing technological advancements in the field of medical devices is also projected to shape industry growth.

Back in March 2021, MedAlliance obtained U.S. FDA approval for its breakthrough device called Sirolimus drug-eluting balloon catheter. This gave patients across the U.S. faster access to the firm’s innovative 90-day sirolimus release tech, which holds the potential to deliver safe and more effective treatment.

DCB catheters ensure a homogenous drug release to the vessel wall for immediate drug delivery, reduce restenosis rates, and help treat peripheral as well as arterial diseases in a minimally invasive manner.

High prices associated with DCB catheter-based treatments may constrain industry outlook. The coronary paclitaxel balloon catheters cost around USD 3,500, which brings them out of the reach of many patients. However, with many nations putting efforts towards attaining universal health coverage (UHC) through strengthening of health systems and introduction of robust financing structures, the impact of high prices is likely to be dampened in coming years.

The global drug-eluting balloon catheters market landscape is bifurcated into different segments such as product, end-use, and regional outlook.

On the basis of product, the industry is categorized into coronary artery disease DCB catheters and peripheral vascular disease DCB catheters. Amongst them, the peripheral vascular disease drug-coated balloon catheters are expected to witness substantial gains, fueled by their efficacy in drug release and increasing cases of peripheral disorders. Peripheral vascular disease DCB catheters help prevent restenosis, which ensures patient safety during surgeries.

With respect to end-use, the industry is classified into ambulatory surgical centers, hospitals and clinics, and catheterization laboratories. The market is slated to witness surging demand from the hospitals and clinics segment owing to increasing cases of cardiovascular diseases and rising hospital admissions for the treatment of such heart-related ailments.

Apart from CVDs, peripheral artery diseases are also some of the prominent ailments contributing towards hospitalizations for catheterization. The presence of a favorable clinical environment across hospitals and clinics and availability of more sophisticated equipment is also influencing segment growth.

From the regional viewpoint, the market is classified into North America, Asia Pacific, Europe, Latin America, and MEA. The Latin America drug-eluting balloon catheters industry is anticipated to expand at a notable rate, owing to the rising prevalence of cardiovascular diseases (CVDs) in the region. CVDs are considered one of the leading causes of deaths across LATAM, responsible for over a million deaths annually. Stroke and coronary heart disease account for 28.8% and 42.5% of cardiovascular disease mortality in the region, respectively.